Covered recipient · General Payments record
REBECCA M DURAN
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$2,171.50
- Reported across 108 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $297.77 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $80.60 | 4 |
| ABBVIE INC. | $50.11 | 3 |
| Organon LLC | $35.18 | 1 |
| Corcept Therapeutics | $31.35 | 2 |
| Acerta Pharma LLC | $27.26 | 2 |
| Exact Sciences Corporation | $21.35 | 1 |
| GlaxoSmithKline, LLC. | $19.17 | 1 |
| PFIZER INC. | $18.64 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $14.11 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $21.33 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107052083 | CMS |
| ABBVIE INC. | $15.29 | 09/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107052085 | CMS |
| ABBVIE INC. | $13.49 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107052087 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.24 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105759451 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.02 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104630612 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $14.11 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086281726 | CMS |
| Corcept Therapeutics | $18.21 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117766825 | CMS |
| Corcept Therapeutics | $13.14 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117766847 | CMS |
| Exact Sciences Corporation | $21.35 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114516969 | CMS |
| GlaxoSmithKline, LLC. | $19.17 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116403663 | CMS |
| Novo Nordisk Inc | $14.88 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100601655 | CMS |
| Novo Nordisk Inc | $20.49 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100322014 | CMS |
| Novo Nordisk Inc | $22.61 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100262506 | CMS |
| Novo Nordisk Inc | $22.62 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100235848 | CMS |
| Organon Llc | $35.18 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136292889 | CMS |
| PFIZER INC. | $18.64 | 06/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131546807 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.